Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $2.4 million.

  • Protalix BioTherapeutics' Net Income towards Common Stockholders fell 2540.17% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 15676.66%. This contributed to the annual value of $2.9 million for FY2024, which is 4383.14% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Net Income towards Common Stockholders stood at $2.4 million for Q3 2025, which was down 2540.17% from $164000.0 recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Net Income towards Common Stockholders registered a high of $16.2 million during Q2 2023, and its lowest value of -$11.4 million during Q2 2021.
  • In the last 5 years, Protalix BioTherapeutics' Net Income towards Common Stockholders had a median value of -$3.2 million in 2022 and averaged -$1.9 million.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Net Income towards Common Stockholders crashed by 217987.42% in 2021, and later surged by 40388.08% in 2023.
  • Over the past 5 years, Protalix BioTherapeutics' Net Income towards Common Stockholders (Quarter) stood at -$6.6 million in 2021, then soared by 51.47% to -$3.2 million in 2022, then crashed by 88.29% to -$6.0 million in 2023, then surged by 207.45% to $6.5 million in 2024, then plummeted by 62.83% to $2.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at $2.4 million for Q3 2025, versus $164000.0 for Q2 2025 and -$3.6 million for Q1 2025.